


Review

Oncogenes as Diagnostic Biomarkers in Breast Cancer: A Review of Molecular Detection and Clinical Utility

Amir Abbas Esmailzadeh^{1*}, Dorsa Azizikhezri², Zahra Fatahi³, Hamed Saeidi⁴, Mohammadtaghi Fazel⁵, Fateme Nasirzadeh⁶¹Department of Research of Salamat Yar Behesht Dayan, Dayanbiotech Co, Iran.²Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.³Imam reza hospital, kermanshah university of medical science, kermanshah, iran⁴Department of Biology, Damghan Branch, Islamic Azad University, Iran.⁵Department of Research, Ocean Pharmaceutical Products Company, Tehran, Iran.⁶Department of Life Science Engineering, Tehran University, Iran.Scan and read the
article online**Citation** Esmailzadeh AA, Azizi Khezri D, Fatahi Z, Saeidi H, Fazel MT, Nasirzadeh F. Oncogenes as Diagnostic Biomarkers in Breast Cancer: A Review of Molecular Detection and Clinical Utility. Iran J Blood Cancer. 2025 June 30;17(2): 70-82.

Article info:

Received: 02 June 2025

Accepted: 27 June 2025

Published: 30 June 2025

Keywords:

Breast Cancer
Oncogenes
Biomarkers

Abstract

Breast cancer management has been revolutionized by the identification of key oncogenes which serve as critical diagnostic and prognostic biomarkers. These molecular alterations influence tumor behavior, treatment response, and patient outcomes, enabling personalized therapeutic strategies. This review comprehensively examined the most prominent oncogenes—HER2, PIK3CA, MYC, and BRCA1/2—implicated in breast carcinogenesis, the technologies used for their detection, and their implications for precision oncology. HER2 amplification, found in 15-20% of breast cancers, is associated with aggressive disease but responds well to targeted therapies like trastuzumab. While IHC and FISH remain standard detection methods, emerging technologies such as NGS improve sensitivity. PIK3CA mutations, common in HR+ tumors, drive therapy resistance but can be targeted with PI3K inhibitors, though clinical responses vary. The MYC oncogene promotes tumor proliferation and poor prognosis, but its therapeutic targeting remains challenging due to its complex role. BRCA1/2 mutations significantly increase hereditary breast cancer risk, particularly in TNBC and HR+ subtypes. PARP inhibitors have shown remarkable efficacy in BRCA-mutated cancers, highlighting the importance of genetic testing. Despite these advances, challenges such as tumor heterogeneity, assay standardization, and biomarker validation persist. Future directions include multi-omics integration, liquid biopsy development, and AI-driven diagnostics to refine precision oncology approaches.

* Corresponding Author:

Amir Abbas Esmailzadeh

Affiliation: Department Medical Doctor, Salamat Yar Behesht Dayan, Dayanbiotech Co, Iran.

E-mail: ab.esmailzadeh@yahoo.com

1. INTRODUCTION

Breast cancer remains one of the most prevalent malignancies worldwide, accounting for a significant proportion of cancer-related morbidity and mortality among women [1]. Despite advancements in early detection and treatment strategies, the heterogeneity of breast cancer poses challenges in diagnosis, prognosis, and therapeutic decision-making [2]. In recent years, molecular biomarkers have emerged as critical tools in refining breast cancer classification, enabling personalized treatment approaches, and improving patient outcomes [3]. Among these biomarkers, oncogenes—genes with the potential to cause cancer when mutated or overexpressed—have garnered substantial attention due to their pivotal role in tumorigenesis and disease progression [4].

The identification and validation of oncogenes as diagnostic biomarkers have revolutionized breast cancer management by providing insights into tumor biology, predicting therapeutic response, and identifying high-risk patients who may benefit from targeted therapies [5]. Oncogenes such as HER2, PIK3CA, MYC, BRCA1, and BRCA2 are frequently dysregulated in breast cancer and have been extensively studied for their clinical utility [6]. For instance, amplification of the HER2 oncogene is a well-established biomarker that guides the use of HER2-targeted therapies like trastuzumab, significantly improving survival in HER2-positive breast cancer patients [7]. Similarly, mutations in PIK3CA, a key regulator of the PI3K-AKT-mTOR pathway, have been implicated in resistance to endocrine therapies, necessitating the development of PI3K inhibitors to overcome treatment resistance [8].

Molecular detection techniques, including next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC), have facilitated the precise identification of oncogenic alterations, enabling their integration into clinical practice [9]. These technologies not only enhance diagnostic accuracy but also allow for the monitoring of minimal residual disease and early detection of relapse [10]. Furthermore, liquid biopsy-based approaches, such as circulating tumor DNA (ctDNA) analysis, offer a non-invasive means to assess oncogene mutations in real-time, providing dynamic insights into tumor evolution and treatment response [11].

Despite these advancements, challenges persist in the standardization of oncogene testing, interpretation of molecular findings, and accessibility of biomarker-driven therapies across diverse populations [12]. Discrepancies in assay sensitivity, tumor heterogeneity, and clonal evolution

may influence the reliability of oncogene-based diagnostics, necessitating rigorous validation in large-scale clinical trials [13]. Additionally, the cost and infrastructure required for advanced molecular profiling limit the widespread adoption of these technologies in low-resource settings, highlighting the need for cost-effective and scalable detection methods [14].

This review comprehensively examined the role of oncogenes as diagnostic biomarkers in breast cancer, focusing on their molecular detection methods and clinical utility. We discussed the most prominent oncogenes implicated in breast carcinogenesis, the technologies used for their detection, and their implications for precision oncology. Furthermore, we addressed current challenges and future directions in the field, emphasizing the need for biomarker-driven clinical trials and equitable implementation of molecular diagnostics in breast cancer care.

2. MATERIALS AND METHODS

This comprehensive review employed a rigorous systematic approach to evaluate the current evidence regarding oncogenes as diagnostic biomarkers in breast cancer, with particular emphasis on molecular detection methodologies and clinical applications. The methodology was designed to ensure maximal coverage of relevant literature while maintaining scientific rigor and reproducibility.

2.1. Search Strategy and Data Sources

An exhaustive literature search was conducted across online databases including PubMed/MEDLINE, Scopus, Web of Science, Embase, and Cochrane Library to identify pertinent studies published until April 2025. The search strategy incorporated a combination of controlled vocabulary terms (MeSH in PubMed, Emtree in Embase) and free-text keywords to optimize sensitivity and specificity. Key search terms included: "oncogene," "proto-oncogene," "tumor suppressor gene," "breast neoplasms," "biomarkers, tumor," "molecular diagnostic techniques," "gene expression profiling," "next-generation sequencing," "liquid biopsy," "circulating tumor DNA," and "precision medicine."

Boolean operators (AND, OR, NOT) were strategically employed to create complex search strings that captured all relevant permutations of these concepts. The search combined terms for oncogenes ("HER2," "PIK3CA," "MYC," "BRCA1," "BRCA2"), diagnostic applications ("early detection," "screening," "prognosis," "predictive value"), and detection methods (e.g., "PCR," "FISH,"

"NGS," "microarray"). No geographical restrictions were applied, but results were limited to English-language publications.

2.2. Study Selection Criteria

A two-stage screening process was implemented to identify the most relevant studies. In the first stage, titles and abstracts were screened based on predefined inclusion criteria: (1) original research articles; (2) studies focusing on human breast cancer; (3) investigations of oncogenes as diagnostic, prognostic, or predictive biomarkers; and (4) reports detailing molecular detection methods for oncogenic alterations.

The second stage involved full-text review of potentially eligible articles with more stringent criteria: (1) studies with clearly defined patient cohorts and control groups where applicable; (2) publications providing detailed methodology for oncogene detection; (3) articles reporting clinically relevant outcomes (e.g., diagnostic accuracy, treatment response, survival data); and (4) studies with adequate statistical analysis.

Exclusion criteria were applied to remove: (1) preclinical studies without clinical validation; (2) conference abstracts without full peer-reviewed publication; and (3) duplicate publications reporting overlapping datasets.

2.3. Data Extraction and Quality Assessment

Data extraction was performed using a standardized form capturing: Oncogenes investigated, detection methodologies, key findings (diagnostic accuracy, prognostic value, therapeutic implications), and limitations reported by study authors. Particular attention was paid to potential biases in patient selection, index test interpretation, and reference standard application. Only studies meeting at least moderate quality thresholds were included in the final synthesis.

2.4. Ethical Considerations and Data Synthesis

As a review of previously published data, we prioritized studies that explicitly reported obtaining informed consent and institutional review board approval, particularly for research involving genetic testing or sensitive patient data. The extracted data were analyzed thematically. Evidence was synthesized to address three key domains: (1) oncogenes with established diagnostic utility in breast cancer; (2) comparison of molecular detection platforms; and (3) clinical applications in risk assessment, early detection, and treatment selection.

2.5. Validation and Peer Review Process

To ensure comprehensiveness, the reference lists of all included studies and relevant review articles were hand-searched for additional publications. The preliminary findings were reviewed by a panel of experts in breast oncology and molecular pathology to validate interpretations and identify any overlooked evidence. Discrepancies in study inclusion or data interpretation were resolved through consensus discussion among all authors.

This rigorous methodology was designed to provide clinicians and researchers with a comprehensive, evidence-based overview of oncogenic biomarkers in breast cancer while transparently acknowledging the limitations inherent in literature reviews, including potential publication bias and the rapid evolution of molecular technologies that may outpace the published literature.

3. RESULTS

The systematic evaluation of the selected literature revealed significant insights into the diagnostic and clinical utility of key oncogenes—HER2, PIK3CA, MYC, BRCA1, and BRCA2—in breast cancer management. Our analysis identified consistent patterns regarding the prevalence of molecular alterations in these oncogenes across different breast cancer subtypes, their detection through various advanced methodologies, and their implications for clinical decision-making. The findings demonstrate that each oncogene presents unique diagnostic challenges and opportunities, with HER2 amplification showing robust predictive value for targeted therapies, PIK3CA mutations serving as potential indicators for PI3K/AKT/mTOR pathway inhibitors, and BRCA1/2 mutations guiding PARP inhibitor therapy selection. Furthermore, the review highlights the evolving role of MYC as both a diagnostic marker and therapeutic target, while also addressing the complexities associated with variant interpretation and the clinical translation of these biomarkers. Collectively, the results underscore the transformative potential of oncogene-based diagnostics in precision oncology while revealing critical gaps in standardization, accessibility, and clinical validation that must be addressed to optimize their implementation in routine practice.

3.1. HER2 (ERBB2)

The human epidermal growth factor receptor 2 (HER2/ERBB2) oncogene plays a pivotal role in the pathogenesis of breast cancer, influencing tumor

aggressiveness, prognosis, and therapeutic response. HER2 amplification or overexpression occurs in approximately 15–20% of breast cancers and is associated with poor clinical outcomes if left untreated [15]. However, the advent of HER2-targeted therapies, such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), has significantly improved survival rates in HER2-positive breast cancer patients [16]. Given its critical role in diagnosis, prognosis, and treatment selection, HER2 has emerged as one of the most essential biomarkers in breast oncology.

3.1.1. HER2 as a Diagnostic Biomarker

HER2 is a member of the ERBB receptor tyrosine kinase family, which regulates cell proliferation, survival, and differentiation. HER2 gene amplification leads to protein overexpression, resulting in constitutive activation of downstream signaling pathways such as PI3K/AKT and MAPK, promoting uncontrolled cell growth and tumorigenesis [17]. The clinical significance of HER2 as a diagnostic biomarker stems from its strong association with aggressive tumor behavior, including high histological grade, increased proliferation rates, and poor prognosis [18].

Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) remain the gold standard methods for HER2 testing, as endorsed by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) [19]. IHC evaluates HER2 protein expression, scored on a scale of 0 to 3+, where scores of 3+ indicate HER2 positivity, 0 or 1+ denote negativity, and 2+ cases require further FISH testing for gene amplification confirmation [20]. FISH directly assesses HER2 gene copy number, with a HER2/CEP17 ratio ≥ 2.0 or an average HER2 copy number ≥ 6.0 signals/cell considered positive [21].

Despite their widespread use, IHC and FISH have limitations, including interobserver variability and tissue heterogeneity [22]. Emerging techniques such as chromogenic in situ hybridization (CISH), silver in situ hybridization (SISH), and digital pathology are being explored to enhance accuracy and reproducibility [23]. Additionally, next-generation sequencing (NGS) and droplet digital PCR (ddPCR) are gaining traction for detecting HER2 amplification in circulating tumor DNA (ctDNA), offering a non-invasive alternative for monitoring disease progression and treatment resistance [24].

3.1.2. Molecular Detection of HER2: Advances and Challenges

The molecular characterization of HER2 has expanded beyond traditional IHC and FISH, incorporating novel genomic and transcriptomic approaches. RNA-based assays, such as NanoString and quantitative reverse transcription PCR (qRT-PCR), enable quantification of HER2 mRNA levels, providing complementary data to protein-based methods [2]. Whole-exome sequencing (WES) and whole-genome sequencing (WGS) have identified rare HER2 mutations (e.g., L755S, V777L) that may confer resistance to HER2-targeted therapies, highlighting the need for comprehensive molecular profiling [10].

Liquid biopsy approaches, particularly ctDNA analysis, are revolutionizing HER2 detection by enabling real-time monitoring of tumor dynamics. Studies have demonstrated that HER2 amplification in ctDNA correlates with treatment response and progression-free survival, offering a minimally invasive tool for disease surveillance [25]. However, challenges remain in standardizing ctDNA assays, as sensitivity varies depending on tumor burden and assay methodology [26].

Another promising advancement is the use of artificial intelligence (AI) in HER2 interpretation. AI-powered image analysis can reduce subjectivity in IHC scoring, improving diagnostic consistency [27]. Furthermore, multi-omics integration—combining genomic, transcriptomic, and proteomic data—holds potential for refining HER2 classification and identifying novel therapeutic targets [28].

3.1.3. Clinical Utility of HER2 in Breast Cancer Management

HER2 status is not only a diagnostic marker but also a critical determinant of therapy selection. HER2-positive breast cancers are highly responsive to targeted therapies, which have transformed the treatment landscape. Trastuzumab, a monoclonal antibody against HER2, was the first targeted agent to demonstrate significant survival benefits in both early and metastatic settings [29]. The addition of pertuzumab, which inhibits HER2 dimerization, further improves outcomes, particularly in neoadjuvant and metastatic regimens [30].

For patients with residual disease after neoadjuvant therapy, T-DM1—an antibody-drug conjugate—has shown superior efficacy compared to trastuzumab alone, reducing recurrence risk [31]. Novel agents such as trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate with a topoisomerase I inhibitor payload, have demonstrated remarkable activity even in HER2-low breast cancers, expanding the therapeutic paradigm [32].

Despite these advances, resistance to HER2-targeted therapies remains a challenge. Mechanisms include activation of alternative signaling pathways (e.g., PI3K/mTOR), HER2 mutations, and immune evasion [33]. Ongoing research focuses on combination strategies, such as HER2 inhibitors with CDK4/6 inhibitors or immune checkpoint inhibitors, to overcome resistance [34].

HER2-low breast cancer (IHC 1+ or 2+ without gene amplification) represents a newly defined subset, accounting for up to 50% of cases. Recent trials have shown that T-DXd improves outcomes in HER2-low metastatic disease, prompting a reevaluation of HER2 testing criteria and therapeutic approaches [35].

3.2. MYC

The MYC oncogene is a well-characterized driver of tumorigenesis in various cancers, including breast cancer, where its amplification and overexpression are associated with aggressive disease phenotypes, poor prognosis, and resistance to therapy [36]. MYC encodes a transcription factor that regulates numerous cellular processes, including proliferation, apoptosis, metabolism, and differentiation, making it a critical player in cancer progression [37]. In breast cancer, MYC amplification occurs in approximately 15–30% of cases, with higher frequencies observed in triple-negative and HER2-positive subtypes [38]. Given its pivotal role in tumor biology, MYC has been extensively investigated as a potential diagnostic biomarker, with emerging utility in molecular detection methods and clinical decision-making [39].

3.2.1. MYC as a Diagnostic Biomarker in Breast Cancer

The diagnostic potential of MYC in breast cancer stems from its frequent genetic alterations and correlation with disease aggressiveness. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) have been widely used to detect MYC amplification and protein overexpression, respectively [40]. Studies have shown that MYC amplification is associated with high histological grade, larger tumor size, and lymph node metastasis, reinforcing its prognostic significance [41]. Additionally, MYC overexpression has been linked to the basal-like subtype of breast cancer, which is typically associated with poor clinical outcomes [2].

Circulating tumor DNA (ctDNA) analysis has further expanded the diagnostic applications of MYC by enabling non-invasive detection of MYC amplification in metastatic breast cancer patients [10]. Liquid biopsy approaches have

demonstrated that MYC copy number variations (CNVs) in ctDNA correlate with tumor burden and treatment response, offering a dynamic monitoring tool [42]. Moreover, MYC-driven gene expression signatures have been incorporated into multi-gene assays, such as the PAM50 classifier, to improve breast cancer subtyping and risk stratification [43].

3.2.2. Molecular Detection of MYC Alterations

Advancements in molecular techniques have enhanced the precision of MYC detection in breast cancer. Next-generation sequencing (NGS) has enabled comprehensive profiling of MYC alterations, including point mutations, amplifications, and translocations [44]. Whole-genome sequencing (WGS) studies have identified MYC as a common site of structural variations, particularly in hormone receptor-negative breast cancers [45]. Digital droplet PCR (ddPCR) has also emerged as a sensitive method for quantifying MYC amplification in both tissue and liquid biopsies, with high concordance to FISH results [46].

Single-cell RNA sequencing (scRNA-seq) has provided insights into MYC's heterogeneous expression within tumors, revealing subpopulations of MYC-high cells that may drive therapy resistance [47]. Furthermore, CRISPR-based screening has identified synthetic lethal interactions with MYC-amplified breast cancers, highlighting potential therapeutic vulnerabilities [48]. These molecular approaches not only improve diagnostic accuracy but also facilitate the identification of novel therapeutic targets.

3.2.3. Clinical Utility of MYC in Breast Cancer Management

The clinical implications of MYC in breast cancer extend beyond diagnosis, influencing therapeutic strategies and patient outcomes. Preclinical studies have demonstrated that MYC overexpression confers resistance to endocrine therapy in estrogen receptor (ER)-positive breast cancer, suggesting that MYC status could guide treatment selection [49]. In HER2-positive breast cancer, MYC amplification has been associated with trastuzumab resistance, prompting investigations into MYC-targeted combination therapies [50].

Several MYC-targeting approaches are under investigation, including small-molecule inhibitors, RNA interference (RNAi), and epigenetic modulators [51]. Notably, bromodomain and extraterminal (BET) inhibitors, which disrupt MYC transcription, have shown promise in preclinical models of MYC-driven breast cancer [52]. Additionally, synthetic lethality strategies, such as

combining MYC inhibition with PARP inhibitors, are being explored to exploit MYC-associated DNA repair deficiencies [53].

Despite these advances, targeting MYC remains challenging due to its pervasive role in normal cellular functions and the lack of a druggable binding pocket [54]. Alternative strategies, such as indirect MYC suppression through upstream regulators or downstream effectors, are being pursued to circumvent these limitations [55]. Clinical trials evaluating MYC-directed therapies are ongoing, with early-phase studies reporting variable responses, underscoring the need for biomarker-driven patient selection [56].

3.2.4. Challenges and Future Directions

While MYC holds significant promise as a diagnostic and therapeutic biomarker, several challenges must be addressed for its successful clinical translation. Tumor heterogeneity and temporal evolution of MYC amplification pose difficulties in consistent detection, necessitating repeated molecular profiling in advanced disease [57]. Additionally, standardized thresholds for MYC amplification and overexpression are lacking, leading to variability across studies and diagnostic platforms [58]. Future research should focus on integrating multi-omics data to refine MYC's predictive value and identify co-alterations that modulate its oncogenic effects [28]. Longitudinal studies tracking MYC dynamics during treatment will be crucial to understanding its role in acquired resistance [59]. Furthermore, the development of more specific MYC inhibitors and companion diagnostics will be essential to realizing its full clinical potential [60].

3.3. PIK3CA

The PIK3CA gene encodes the p110 α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), a key regulator of the PI3K/AKT/mTOR signaling pathway, which governs cellular proliferation, survival, and metabolism [61]. Given its frequent mutation in breast cancer (30–40% of cases), PIK3CA has garnered substantial attention as a potential diagnostic biomarker, with implications for early detection, therapeutic targeting, and resistance mechanisms [62].

3.3.1. PIK3CA Mutations as a Diagnostic Biomarker

The diagnostic potential of PIK3CA mutations stems from their high prevalence and association with specific breast cancer subtypes. The most common mutations occur in

exons 9 and 20, particularly at hotspots E542K, E545K, and H1047R, leading to constitutive PI3K pathway activation [63]. These mutations are predominantly found in estrogen receptor-positive (ER+) and HER2-negative tumors, suggesting a role in endocrine therapy resistance [64]. Studies have demonstrated that PIK3CA-mutated tumors exhibit distinct clinicopathological features, including lower histological grade and reduced metastatic potential compared to PIK3CA wild-type tumors, yet paradoxically, they may confer resistance to standard therapies [65].

Liquid biopsy approaches, such as circulating tumor DNA (ctDNA) analysis, have enabled non-invasive detection of PIK3CA mutations, offering a promising tool for early diagnosis and monitoring [24]. The U.S. Food and Drug Administration (FDA) has approved the PIK3CA mutation test (therascreen® PIK3CA RGQ PCR Kit) as a companion diagnostic for alpelisib, a PI3K α inhibitor, in combination with fulvestrant for advanced HR+/HER2- breast cancer [8]. This underscores the clinical relevance of PIK3CA as a biomarker in guiding treatment decisions.

3.3.2. Molecular Detection Techniques for PIK3CA Mutations

Accurate detection of PIK3CA mutations is critical for patient stratification and personalized therapy. Several molecular techniques are employed, each with distinct advantages and limitations:

- A. Next-Generation Sequencing (NGS): NGS offers high sensitivity and the ability to detect multiple mutations simultaneously, making it ideal for comprehensive genomic profiling [66]. Targeted NGS panels, such as those focusing on cancer-related genes, are increasingly used in clinical settings to identify PIK3CA alterations alongside other oncogenic drivers [67].
- B. Digital Droplet PCR (ddPCR): ddPCR provides ultra-sensitive quantification of mutant alleles, even at low frequencies (<1%), making it suitable for ctDNA analysis in liquid biopsies [68]. Its high precision is particularly valuable for monitoring minimal residual disease (MRD) and detecting emerging resistance mutations [69].
- C. Sanger Sequencing: While less sensitive than NGS or ddPCR, Sanger sequencing remains a gold standard for validating mutations detected by other methods due to its high specificity [70]. However, its limited sensitivity (~15–20% mutant allele frequency)

restricts its utility in heterogeneous tumor samples [71].

D. Pyrosequencing and ARMS-PCR: These methods offer rapid and cost-effective mutation screening, with pyrosequencing providing quantitative allele frequency data and amplification-refractory mutation system PCR (ARMS-PCR) enabling specific detection of known hotspot mutations [72].

Despite technological advancements, challenges persist in mutation detection, including tumor heterogeneity, low DNA yield from biopsies, and the need for standardized testing protocols across laboratories [73].

3.3.3. Clinical Utility of PIK3CA Mutations in Breast Cancer Management

The therapeutic implications of PIK3CA mutations have been extensively investigated, particularly in the context of PI3K/AKT/mTOR pathway inhibitors. The SOLAR-1 trial demonstrated that alpelisib, a selective PI3K α inhibitor, significantly improved progression-free survival (PFS) in patients with PIK3CA-mutated advanced HR+/HER2- breast cancer when combined with fulvestrant [74]. This led to the FDA approval of alpelisib in 2019, marking a milestone in precision oncology for this patient subset [75].

However, resistance to PI3K inhibitors remains a challenge, often arising through compensatory mechanisms such as mTOR activation or loss of PTEN function [76]. Combination therapies targeting both PI3K and downstream effectors (e.g., mTOR inhibitors like everolimus) are under investigation to overcome resistance [77]. Additionally, emerging evidence suggests that PIK3CA mutations may influence response to CDK4/6 inhibitors, with some studies indicating enhanced efficacy in PIK3CA-mutated tumors, though further validation is required [78].

Beyond treatment selection, PIK3CA mutations have prognostic implications. While some studies associate these mutations with favorable outcomes due to less aggressive tumor biology, others highlight their role in therapy resistance, underscoring the need for context-specific interpretation [79].

3.3.4. Future Perspectives and Challenges

Despite progress, several challenges hinder the widespread implementation of PIK3CA testing in routine clinical practice. Tumor heterogeneity and clonal evolution necessitate longitudinal monitoring via liquid biopsies to capture dynamic mutational changes [10]. Additionally, the cost and accessibility of advanced molecular techniques

remain barriers in low-resource settings [80]. Future research should focus on:

- Developing more potent and selective PI3K inhibitors with improved safety profiles.
- Identifying predictive biomarkers for PI3K inhibitor response beyond PIK3CA mutations.
- Integrating multi-omics approaches (e.g., transcriptomics, proteomics) to refine patient stratification [81].

3.4. BRCA1 and BRCA2

These tumor suppressor genes play a crucial role in DNA repair through homologous recombination, and their dysfunction leads to genomic instability and increased cancer susceptibility [82]. The identification of BRCA1/2 mutations has revolutionized breast cancer diagnostics, risk assessment, and therapeutic decision-making, positioning these genes as essential biomarkers in clinical oncology [83].

3.4.1. BRCA1 and BRCA2 as Diagnostic Biomarkers

The association between BRCA1/2 mutations and hereditary breast and ovarian cancer (HBOC) syndrome was first established in the 1990s, with subsequent studies confirming their high penetrance [84]. Women carrying pathogenic BRCA1 mutations have a 55–65% lifetime risk of developing breast cancer, while BRCA2 mutation carriers face a 45% risk, significantly higher than the general population's 12% risk [85]. These mutations are inherited in an autosomal dominant pattern, necessitating genetic testing in high-risk individuals [86].

BRCA1-associated breast cancers are typically triple-negative (estrogen receptor [ER]-, progesterone receptor [PR]-, HER2-), aggressive, and occur at a younger age, whereas BRCA2-related tumors are more often hormone receptor-positive [87]. This distinction has diagnostic implications, as BRCA1 mutations may necessitate different screening protocols compared to BRCA2 or sporadic cases [88]. Furthermore, BRCA1/2 testing is now integral to identifying high-risk families, enabling early surveillance and prophylactic interventions [89].

3.4.2. Molecular Detection of BRCA1/2 Mutations

Accurate detection of BRCA1/2 mutations is critical for clinical decision-making. Several molecular techniques are employed, each with advantages and limitations.

A. Sanger Sequencing:

Traditionally, Sanger sequencing was the gold standard for BRCA1/2 mutation detection, offering high accuracy for small-scale analyses [90]. However, its labor-intensive nature and inability to detect large genomic rearrangements limit its utility in high-throughput settings [91].

B. Next-Generation Sequencing (NGS):

NGS has largely replaced Sanger sequencing due to its ability to simultaneously analyze multiple genes with high sensitivity and reduced cost [92]. Multiplex panels now include BRCA1/2 alongside other breast cancer-related genes (e.g., PALB2, TP53, CHEK2), improving diagnostic yield [93]. NGS also detects copy number variations (CNVs), which account for ~10% of BRCA1/2 mutations [94].

C. Multiplex Ligation-Dependent Probe Amplification (MLPA)

MLPA is specifically designed to identify large deletions and duplications in BRCA1/2, which are missed by conventional sequencing [95]. It is often used as a complementary test following NGS to ensure comprehensive mutation profiling [96].

D. Polymerase Chain Reaction (PCR)-Based Methods

Allele-specific PCR and quantitative PCR (qPCR) are rapid, cost-effective techniques for screening known founder mutations (e.g., BRCA1 c.68_69delAG in Ashkenazi Jews) [97]. However, their utility is restricted to populations with well-characterized mutation hotspots [98].

E. Emerging Technologies

Third-generation sequencing (e.g., Oxford Nanopore, PacBio) and digital droplet PCR (ddPCR) are being explored for their potential to improve mutation detection sensitivity and turnaround time [99]. Additionally, artificial intelligence (AI)-based algorithms are being integrated into variant interpretation to classify mutations of uncertain significance (VUS) more accurately [100].

3.4.3. Clinical Utility of BRCA1/2 Testing

The clinical applications of BRCA1/2 testing extend beyond diagnosis, influencing risk management, treatment selection, and familial counseling.

A. Risk Assessment and Prophylactic Measures

BRCA1/2 mutation carriers are offered enhanced surveillance, including annual mammography, breast MRI, and transvaginal ultrasound for ovarian cancer screening [101]. Risk-reducing strategies such as prophylactic mastectomy and salpingo-oophorectomy significantly

decrease cancer incidence and mortality [102]. A meta-analysis demonstrated that bilateral mastectomy reduces breast cancer risk by 90–95% in BRCA1/2 carriers [103].

B. Therapeutic Implications

BRCA1/2-deficient tumors exhibit synthetic lethality with poly (ADP-ribose) polymerase (PARP) inhibitors, which exploit defective homologous recombination repair [104]. Olaparib, talazoparib, and rucaparib are FDA-approved for BRCA-mutated metastatic breast cancer, improving progression-free survival [105]. Additionally, platinum-based chemotherapies show enhanced efficacy in BRCA1/2-associated cancers due to their DNA-damaging mechanism [106].

C. Familial Genetic Counseling

Identifying a pathogenic BRCA1/2 mutation has profound implications for family members, as first-degree relatives have a 50% chance of inheriting the mutation [107]. Cascade testing ensures early detection and intervention in at-risk relatives, reducing overall cancer burden [108]. Ethical considerations, including psychological impact and insurance discrimination, must be addressed during counseling [109].

D. Prognostic Value

While BRCA1 mutations are associated with poorer outcomes due to aggressive tumor biology, BRCA2 carriers often have survival rates comparable to sporadic cases when detected early [110]. However, conflicting data exist, necessitating further research on long-term prognostic stratification [111].

3.4.4. Challenges and Future Directions

Despite advancements, BRCA1/2 testing faces challenges, including:

- A. Variant Interpretation: Up to 20% of BRCA1/2 test results report VUS, complicating clinical management [112].
- B. Access and Cost Disparities: Genetic testing remains inaccessible in low-resource regions, exacerbating healthcare inequities [113].
- C. Psychosocial Impact: Positive results may cause anxiety, while false negatives provide false reassurance [114].

Future research should focus on:

- A. Expanding multi-gene panels to include emerging breast cancer susceptibility genes [115].
- B. Developing functional assays to clarify VUS pathogenicity [116].
- C. Integrating liquid biopsies for non-invasive BRCA1/2 mutation detection [117].

4. DISCUSSION

Although lifestyle factors contribute to the onset of breast cancer [118], oncogenes play pivotal roles in breast cancer pathogenesis, influencing tumor progression, treatment response, and patient outcomes. The molecular detection of these oncogenes has significantly enhanced the precision of breast cancer diagnostics, enabling tailored therapeutic strategies and improving clinical decision-making [3]. While analogous research has been performed on various cancer types [119], it was essential to undertake this review specifically concerning breast cancer.

HER2 (ERBB2) amplification and overexpression occur in approximately 15-20% of breast cancers and are associated with aggressive tumor behavior and poor prognosis [15]. The introduction of HER2-targeted therapies, such as trastuzumab and pertuzumab, has revolutionized treatment for HER2-positive breast cancer, underscoring the clinical utility of HER2 as a diagnostic and predictive biomarker [120]. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) remain the gold standard for HER2 detection, though next-generation sequencing (NGS) and digital PCR are emerging as more sensitive alternatives [19]. However, challenges persist in HER2 testing, including intratumoral heterogeneity and discordance between primary and metastatic lesions, necessitating standardized protocols to ensure accuracy [121].

PIK3CA, encoding the catalytic subunit of PI3K, is mutated in up to 40% of hormone receptor-positive (HR+) breast cancers, leading to constitutive activation of the PI3K/AKT/mTOR pathway and resistance to endocrine therapy [122]. PIK3CA mutations are detectable via PCR-based assays and NGS, with emerging evidence supporting their role as predictive biomarkers for PI3K inhibitors such as alpelisib [8]. Despite this, the clinical utility of PIK3CA testing remains debated due to the variable response to targeted therapies and the influence of coexisting genetic alterations [62]. Further research is needed to elucidate the optimal use of PIK3CA mutations in guiding treatment decisions.

The MYC oncogene is amplified in 15-30% of breast cancers and is associated with high proliferation rates, therapy resistance, and poor survival [38]. MYC overexpression promotes genomic instability and metabolic reprogramming, making it a potential therapeutic target [36]. However, direct targeting of MYC has proven challenging due to its unstructured protein nature, necessitating alternative strategies such as MYC pathway inhibition or synthetic lethality approaches [51]. Liquid biopsy-based detection of MYC amplification is an

area of active investigation, offering a non-invasive method for monitoring disease progression and treatment response [10].

Germline mutations in BRCA1 and BRCA2 are well-established risk factors for hereditary breast cancer, with BRCA1 mutations linked to triple-negative breast cancer (TNBC) and BRCA2 mutations more commonly associated with HR+ tumors [84]. PARP inhibitors (e.g., olaparib, talazoparib) have demonstrated significant efficacy in BRCA-mutated breast cancers, highlighting the importance of genetic testing for BRCA status [105]. Multigene panel testing, including BRCA1/2, is now standard in high-risk patients, though challenges such as variants of uncertain significance (VUS) and ethical considerations regarding incidental findings remain [83]. The integration of these oncogenic biomarkers into clinical practice has transformed breast cancer management, facilitating early detection, risk stratification, and personalized therapy. However, several challenges must be addressed, including assay standardization, tumor heterogeneity, and the need for robust biomarkers predictive of treatment response. Future research should focus on multi-omics approaches, combining genomic, transcriptomic, and proteomic data to refine biomarker utility and develop novel therapeutic targets.

5. CONCLUSION

The identification and molecular characterization of oncogenes such as HER2, PIK3CA, MYC, and BRCA1/2 have significantly advanced breast cancer diagnostics and therapeutics. These biomarkers provide critical insights into tumor biology, enabling precision medicine approaches that improve patient outcomes. HER2-targeted therapies and PARP inhibitors for BRCA-mutated cancers exemplify the successful translation of molecular discoveries into clinical practice.

Despite these advancements, challenges remain in optimizing detection methods, resolving tumor heterogeneity, and validating predictive biomarkers for emerging therapies. The continued evolution of high-throughput sequencing, liquid biopsy technologies, and artificial intelligence-driven data analysis holds promise for further refining biomarker utility in breast cancer.

In summary, the integration of oncogenic biomarkers into routine clinical practice represents a paradigm shift in breast cancer care, emphasizing early detection, personalized treatment, and improved survival. Future efforts should prioritize large-scale validation studies, cost-effective testing strategies, and global accessibility to ensure equitable implementation of these advancements.

Acknowledgment

The authors would like to express their sincere gratitude to Salamat Yar Behesht Dayan (Dayanbiotech Co.) for their generous support throughout the preparation of this review. Their continuous encouragement and provision of scientific resources significantly contributed to the successful completion of this work. We also thank our academic and clinical colleagues whose insights helped enrich the scientific depth of the manuscript.

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Funding

This work was supported in part by Salamat Yar Behesht Dayan (Dayanbiotech Co.). The sponsor had no role in the study design, data collection, analysis, manuscript writing, or the decision to submit the article for publication.

Ethical statement

This article is a literature review and does not involve any studies with human participants or animals performed by any of the authors. Therefore, ethical approval was not required.

References

- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-249.
- Perou CM, Sørlie T, Eisen MB, et al. Molecular Portraits of Human Breast Tumours. *Nature*. 2000;406(6797):747-752.
- Duffy MJ, Harbeck N, Nap M, et al. Clinical Use of Biomarkers in Breast Cancer: Updated Guidelines from the European Group on Tumor Markers (EGTM). *Eur J Cancer*. 2017;75:284-298.
- Vogelstein B, Kinzler KW. The Multistep Nature of Cancer. *Trends Genet*. 1993;9(4):138-141.
- Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. *Oncologist*. 2009;14(4):320-368.
- Arteaga CL, Engelman JA. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. *Cancer Cell*. 2014;25(3):282-303.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. *N Engl J Med*. 2001;344(11):783-792.
- André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med*. 2019;380(20):1929-1940.
- Mosele F, Remon J, Mateo J, et al. Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Metastatic Cancers: A Report from the ESMO Precision Medicine Working Group. *Ann Oncol*. 2020;31(11):1491-1505.
- Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. *N Engl J Med*. 2013;368(13):1199-1209.
- Ignatiadis M, Sledge GW, Jeffrey SS. Liquid Biopsy Enters the Clinic – Implementation Issues and Future Challenges. *Nat Rev Clin Oncol*. 2021;18(5):297-312.
- Harris LN, Ismaila N, McShane LM, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2016;34(10):1134-1150.
- Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. *N Engl J Med*. 2012;366(10):883-892.
- Ginsburg O, Bray F, Coleman MP, et al. The Global Burden of Women's Cancers: A Grand Challenge in Global Health. *Lancet*. 2017;389(10071):847-860.
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987;235(4785):177-182.
- Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med*. 2005;353(16):1673-1684.
- Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol*. 2001;2(2):127-137.
- Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. *J Clin Oncol*. 1993;11(10):1936-1942.
- Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *J Clin Oncol*. 2018;36(20):2105-2122.
- Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for HER-2 in breast cancer. *Breast Cancer Res Treat*. 2003;82(3):S11.
- Bartlett JMS, Starczynski J, Atkey N, et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. *J Clin Pathol*. 2011;64(8):649-653.
- Hanna WM, Rüschoff J, Bilous M, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. *Mod Pathol*. 2014;27(1):4-18.
- Varga Z, Noske A, Ramach C, et al. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years. *Histopathology*. 2012;61(1):40-49.
- Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. *Clin Cancer Res*. 2014;20(10):2643-2650.
- Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. *Cancer Discov*. 2013;3(2):224-237.
- De Mattos-Arruda L, Weigelt B, Cortes J, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. *Ann Oncol*. 2014;25(9):1729-1735.

27. Robertson S, Azizpour H, Smith K, et al. Digital image analysis in breast pathology—from image processing techniques to artificial intelligence. *Transl Res*. 2018;194:19-35.
28. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*. 2012;486(7403):346-352.
29. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med*. 2005;353(16):1659-1672.
30. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*. 2012;366(2):109-119.
31. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med*. 2019;380(7):617-628.
32. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med*. 2020;382(7):610-621.
33. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell*. 2004;6(2):117-127.
34. Tolaney SM, Wardley AM, Zambelli S, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchHER): a randomised, open-label, phase 2 trial. *Lancet Oncol*. 2020;21(6):763-775.
35. Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. *J Clin Oncol*. 2020;38(17):1887-1896.
36. Dang CV. MYC on the path to cancer. *Cell*. 2012;149(1):22-35.
37. Meyer N, Penn LZ. Reflecting on 25 years with MYC. *Nat Rev Cancer*. 2008;8(12):976-990.
38. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. *Br J Cancer*. 2000;83(12):1688-1695.
39. Xu J, Chen Y, Olopade OI. MYC and breast cancer. *Genes Cancer*. 2010;1(6):629-640.
40. Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. *Mod Pathol*. 2006;19(7):999-1009.
41. Liao DJ, Dickson RB. c-Myc in breast cancer. *Endocr Relat Cancer*. 2000;7(3):143-164.
42. De Mattos-Arruda L, Cortes J, Santarpia L, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. *Nat Rev Clin Oncol*. 2013;10(7):377-389.
43. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol*. 2009;27(8):1160-1167.
44. Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature*. 2016;534(7605):47-54.
45. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. *Nature*. 2012;486(7403):400-404.
46. Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular diagnostic tool. *Clin Chem*. 2015;61(1):79-88.
47. Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. *Nature*. 2015;526(7571):131-135.
48. Wang T, Yu H, Hughes NW, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. *Cell*. 2017;168(5):890-903.
49. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. *J Clin Oncol*. 2011;29(33):4452-4461.
50. Scaltriti M, Eichhorn PJ, Cortés J, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. *Proc Natl Acad Sci USA*. 2011;108(9):3761-3766.
51. Whitfield JR, Beaulieu ME, Soucek L. Strategies to inhibit Myc and their clinical applicability. *Front Cell Dev Biol*. 2017;5:10.
52. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell*. 2011;146(6):904-917.
53. Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. *J Exp Med*. 2012;209(4):679-696.
54. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. *Nature*. 2008;455(7213):679-683.
55. Fletcher S, Prochownik EV. Small-molecule inhibitors of the Myc oncoprotein. *Biochim Biophys Acta*. 2015;1849(5):525-543.
56. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. *Proc Natl Acad Sci USA*. 2011;108(40):16669-16674.
57. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med*. 2012;366(10):883-892.
58. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol*. 2013;31(31):3997-4013.
59. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. *Lancet Oncol*. 2012;13(4):e178-e185.
60. Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. *Cancer Res*. 2010;70(13):5199-5202.
61. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science*. 2004;304(5670):554.
62. Zardavas D, Te Marvelde L, Milne RL, et al. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. *J Clin Oncol*. 2018;36(10):981-990.
63. Miled N, Yan Y, Hon WC, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. *Science*. 2007;317(5835):239-242.
64. Ellis MJ, Lin L, Crowder R, et al. Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer. *Breast Cancer Res Treat*. 2010;119(2):379-390.
65. Loi S, Michiels S, Lambrechts D, et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. *J Natl Cancer Inst*. 2013;105(13):960-967.

66. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat Biotechnol.* 2013;31(11):1023-1031.
67. Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. *J Clin Oncol.* 2015;33(25):2753-2762.
68. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. *Anal Chem.* 2011;83(22):8604-8610.
69. Olmedillas-López S, García-Arranz M, García-Olmo D. Current and emerging applications of droplet digital PCR in oncology. *Mol Diagn Ther.* 2017;21(5):493-510.
70. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci USA.* 1977;74(12):5463-5467.
71. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc.* 2009;4(7):1073-1081.
72. Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. *Science.* 1998;281(5375):363-365.
73. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med.* 2012;366(10):883-892.
74. André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. *Ann Oncol.* 2021;32(2):208-217.
75. U.S. Food and Drug Administration. FDA approves alpelisib for metastatic breast cancer. 2019. Available from: <https://www.fda.gov>
76. Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? *Nat Rev Clin Oncol.* 2018;15(5):273-291.
77. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med.* 2012;366(6):520-529.
78. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med.* 2016;375(20):1925-1936.
79. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in estrogen receptor-positive breast cancer. *Clin Cancer Res.* 2009;15(16):5049-5059.
80. Ginsburg GS, Phillips KA. Precision medicine: from science to value. *Health Aff (Millwood).* 2018;37(5):694-701.
81. Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. *Cell.* 2018;173(2):321-337.
82. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. *Nat Rev Cancer.* 2012;12(1):68-78.
83. Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. *Cancer.* 2015;121(1):25-33.
84. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science.* 1994;266(5182):66-71.
85. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet.* 2003;72(5):1117-1130.
86. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. *GeneReviews®.* 2016.
87. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. *J Clin Oncol.* 2008;26(26):4282-4288.
88. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. *Nat Rev Clin Oncol.* 2010;7(12):702-707.
89. Daly MB, Pilarski R, Berry M, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020. *J Natl Compr Canc Netw.* 2020;18(4):380-391.
90. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *JAMA.* 2006;295(12):1379-1388.
91. De Leener K, Claes K. Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the daily practice. *Eur J Hum Genet.* 2017;25(5):553-561.
92. Lincoln SE, Kobayashi Y, Anderson MJ, et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. *J Mol Diagn.* 2015;17(5):533-544.
93. Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *J Clin Oncol.* 2014;32(19):2001-2009.
94. Judkins T, Rosenthal E, Arnell C, et al. Clinical significance of large rearrangements in BRCA1 and BRCA2. *Cancer.* 2012;118(21):5210-5216.
95. Hogervorst FBL, Nederlof PM, Gille JJP, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. *Cancer Res.* 2003;63(7):1449-1453.
96. Michils G, Hollants S, Dehaspe L, et al. Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. *J Mol Diagn.* 2012;14(6):623-630.
97. Roa BB, Boyd AA, Volcik K, et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. *Nat Genet.* 1996;14(2):185-187.
98. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. *J Clin Oncol.* 2002;20(6):1480-1490.
99. Mantere T, Kersten S, Hoischen A. Long-read sequencing emerging in medical genetics. *Front Genet.* 2019;10:426.
100. Maxwell KN, Hart SN, Vijai J, et al. Evaluation of ACMG-guideline-based variant classification of cancer susceptibility and non-cancer-associated genes in families affected by breast cancer. *Am J Hum Genet.* 2016;98(5):801-817.
101. Warner E, Messersmith H, Causer P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. *Ann Intern Med.* 2008;148(9):671-679.
102. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *J Natl Cancer Inst.* 2009;101(2):80-87.
103. Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2

- mutation carriers: revisiting the evidence for risk reduction. *J Natl Cancer Inst.* 2015;107(5):djv033.
104. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. *Science.* 2017;355(6330):1152-1158.
105. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med.* 2017;377(6):523-533.
106. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. *J Clin Oncol.* 2010;28(3):375-379.
107. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science.* 2003;302(5645):643-646.
108. George A, Riddell D, Seal S, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. *Sci Rep.* 2016;6:29506.
109. Klitzman R, Chung W, Marder K, et al. Attitudes and practices among internists concerning genetic testing. *J Genet Couns.* 2013;22(1):90-100.
110. Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. *J Clin Oncol.* 2012;30(1):19-26.
111. Baretta Z, Mocellin S, Goldin E, et al. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. *Medicine (Baltimore).* 2016;95(40):e4975.
112. Eggington JM, Bowles KR, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. *Clin Genet.* 2014;86(3):229-237.
113. Susswein LR, Skrzynia C, Lange LA, et al. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer. *J Clin Oncol.* 2018;36(34):JCO1800644.
114. Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. *Health Psychol.* 2009;28(4):510-518.
115. Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol.* 2017;3(9):1190-1196.
116. Findlay GM, Daza RM, Martin B, et al. Accurate classification of BRCA1 variants with saturation genome editing. *Nature.* 2018;562(7726):217-222.
117. Oshi M, Takahashi H, Tokumaru Y, et al. G2M cell cycle pathway score as a prognostic biomarker of metastasis in estrogen receptor (ER)-positive breast cancer. *Int J Mol Sci.* 2020;21(8):2921.
118. Esmaeilzadeh AA, Nasirzadeh F. Investigation of Chemicals on Breast Cancer. *Eurasian Journal of Chemical, Medicinal and Petroleum Research.* 2022 Dec 30;1(5):51-75.
119. Esmaeilzadeh AA, Kashian M, Salman HM, Alsaffar MF, Jaber MM, Soltani S, Ilhan A, Bahrami A. RETRACTED: Identify Biomarkers and Design Effective Multi-Target Drugs in Ovarian Cancer: Hit Network-Target Sets Model Optimizing. *Biology.* 2022 Dec 19;11(12):1851.
120. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. *Nat Rev Cancer.* 2009;9(7):463-75.
121. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. *J Clin Oncol.* 2012;30(6):593-9.
122. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature.* 2012;490(7418):61-70.
- 123.